Vincristine sulphate (Oncovin)

Vincristine sulphate (Oncovin) is an intravenous anti-cancer drug derived from the periwinkle plant. It is thought to interfere with cell division. It is being studied as a treatment for Kaposi’s sarcoma and lymphoma, in combination with other anti-cancer drugs. It is manufactured by Eli Lilly.

Side-effects include peripheral neuropathy (numbness or weakness in the limbs due to nerve damage), constipation and occasional hair loss. However, a fat-coated or ‘liposomal’ version of vincristine is less likely to cause neuropathy, while being effective against non-Hodgkin’s lymphoma.1

The drug is given intravenously. The dose and schedule will depend upon what other drugs are being used in combination with vincristine. If used alongside d4T (stavudine, Zerit), ddI (didanosine, Videx / VidexEC) and ddC (zalcitabine, Hivid) it may increase the risk of peripheral neuropathy.


  1. Sarris AH et al. Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Ann Oncol 11: 69-72, 2000

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.